INDUSTRY ACADEMIC COOPERATION FOUNDATION; HALLYM UNIVERSITY
发明人:
CHOI, SU YOUNG,최수영,UM, WON SIK,음원식,KIM, DAE WON,김대원,HWANG, HYUN SOOK,황현숙,PARK, JIN SEO,박진서,KIM, DUK SOO,김덕수,HAN, KYU HYUNG,한규형
申请号：
KR1020110101574
公开号：
KR1020130037269A
申请日:
2011.10.06
申请国别(地区):
KR
年份:
2013
代理人:
摘要：
PURPOSE: A cell permeable metallothionein-III fusion protein is provided to enable effective penetration into cells, to protect cell apoptosis in vivo and in vitro, and to treat ischemic stroke.CONSTITUTION: A cell permeable metallothionein-III fusion protein has a PEP-1 protein transport domain which is bonded at one or more ends of metallothionein-III. A pharmaceutical composition for preventing or treating brain ischemia or neural cell apoptosis contains the metallothionein-III fusion protein as an active ingredient and contains a pharmaceutically acceptable carrier. The metallothionein-III fusion protein contains a protein transport domain bonded at C-terminal and/or N-terminal of metallothionein-III by covalent bond.COPYRIGHT KIPO 2013본 발명은 세포 투과성 메탈로티오네인-Ⅲ 융합 단백질에 관한 것으로서, 좀더 구체적으로는 메탈로티오네인-Ⅲ 융합 단백질이 세포 내로 효율적으로 투과하여 인비트로와 인비보에서 세포사멸을 보호하고, 뇌허혈에 대한 치료제로서의 효능을 밝혔다.
